Well Daan Van Sells 6,168 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Well Van sold 6,168 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $7.63, for a total value of $47,061.84. Following the transaction, the insider owned 338,884 shares of the company’s stock, valued at approximately $2,585,684.92. This represents a 1.79% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

SOPHiA GENETICS Trading Down 0.1%

NASDAQ:SOPH traded down $0.01 during trading hours on Monday, hitting $7.86. The company had a trading volume of 309,330 shares, compared to its average volume of 261,716. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55. The stock has a 50-day moving average price of $7.03 and a 200 day moving average price of $5.69. The company has a market capitalization of $659.38 million, a PE ratio of -6.83 and a beta of 0.98. SOPHiA GENETICS SA has a 52 week low of $3.12 and a 52 week high of $8.98.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The company had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. On average, equities research analysts predict that SOPHiA GENETICS SA will post -0.77 EPS for the current fiscal year.

Hedge Funds Weigh In On SOPHiA GENETICS

Several large investors have recently modified their holdings of SOPH. AWM Investment Company Inc. purchased a new stake in SOPHiA GENETICS during the 2nd quarter valued at about $9,809,000. Principal Financial Group Inc. lifted its stake in shares of SOPHiA GENETICS by 0.7% in the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after buying an additional 9,800 shares in the last quarter. Hodges Capital Management Inc. purchased a new stake in shares of SOPHiA GENETICS during the first quarter valued at approximately $2,157,000. Royce & Associates LP purchased a new stake in shares of SOPHiA GENETICS during the fourth quarter valued at approximately $2,009,000. Finally, Sei Investments Co. purchased a new position in SOPHiA GENETICS in the 1st quarter worth approximately $1,772,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on SOPH shares. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. HC Wainwright upped their price target on SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. BTIG Research raised their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Finally, Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $10.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS Ltd. is a healthcare technology company that develops data-driven medicine solutions for healthcare institutions, pharmaceutical companies and research organizations. The company’s platform is designed to help users analyze complex genomic and multimodal data and apply insights to clinical research and patient care.

Its core offering, the SOPHiA DDM platform, combines cloud-based software, artificial intelligence and machine-learning tools to support the interpretation of genomic data.